Research Topics
Species | Jesus F San-MiguelSummaryAffiliation: Universidad de Salamanca Country: Spain Publications
| Collaborators
|
Detail Information
Publications
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasoneJesus F San-Miguel
Servicio de Hematologia, Hospital Universitario de Salamanca, CIC, IBMCC, Spain
Clin Lymphoma Myeloma Leuk 11:38-43. 2011..In both trials the treatment was continued until disease progression or unacceptable toxicity. We conducted a subanalysis to determine if continuing therapy after achieving?partial response (PR) improved survival...- The DAC system and associations with multiple myelomaEnrique M Ocio
University Hospital of Salamanca, Salamanca, Spain
Invest New Drugs 28:S28-35. 2010..This has prompted the development of combinations such as the one with bortezomib or lenalidomide and dexamethasone, which have already been taken into the clinics with positive preliminary results... - Risk stratification in the era of novel therapiesJesús San-Miguel
Servicio de Hematologia, Hospital Universitario de Salamanca, Paseo de San Vicente, 58, Salamanca 37007, Spain
Cancer J 15:457-64. 2009.... - Bortezomib plus melphalan and prednisone for initial treatment of multiple myelomaJesus F San Miguel
Hospital Universitario Salamanca, CIC, IBMCC USAL CSIC, Salamanca, Spain
N Engl J Med 359:906-17. 2008..This phase 3 study compared the use of melphalan and prednisone with or without bortezomib in previously untreated patients with multiple myeloma who were ineligible for high-dose therapy... - Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 studyJ F San-Miguel
Department of Hematology, Hospital Universitario CIC Universidad de Salamanca CSIC, Salamanca, Spain
Leukemia 22:842-9. 2008..These results indicate that bortezomib is active and well tolerated in patients with relapsed MM with varying degrees of renal insufficiency. Efficacy/safety were not substantially affected by severe-to-moderate vs no/mild impairment... - Individualizing treatment of patients with myeloma in the era of novel agentsJesús San-Miguel
Servicio de Hematologia, Hospital Universitario de Salamanca, Paseo de San Vicente, 58, 37007 Salamanca, Spain
J Clin Oncol 26:2761-6. 2008.... - Conventional diagnostics in multiple myelomaJesus F San Miguel
Servicio de Haematología, Hospital Universitario de Salamanca, Paseo de San Vicente 58 182, 37007, Salamanca, Spain
Eur J Cancer 42:1510-9. 2006..In addition, possible technical pitfalls inherent to each technique will be analysed... - A practical update on the use of bortezomib in the management of multiple myelomaJesus San Miguel
Hematology Department, Hospital Clinico Universitario de Salamanca, Servicio de Hematologia, Paseo de San Vicente 58, Salamanca E 37007, Spain
Oncologist 11:51-61. 2006..Information is given on the practical management of the most common adverse events, including peripheral neuropathy and thrombocytopenia, and the use of bortezomib in renal and hepatic impairment... - Analysis of methylation pattern in multiple myelomaJesús San-Miguel
Servicio de Hematologia, Hospital Universitario de Salamanca, Centro de Investigacion del Cancer, Universidad de Salamanca, Salamanca, Spain
Acta Haematol 114:23-6. 2005..Multiple myeloma remains an incurable disease, so new treatment strategies are needed to improve the outcome of patients... - Prognostic features of multiple myelomaJesus F San Miguel
Department of Hematology, University Hospital of Salamanca, Paseo de San Vicente, 58 182, Salamanca 37007, Spain
Best Pract Res Clin Haematol 18:569-83. 2005.... - Myeloma: update on supportive care strategiesJesus F San Miguel
Department of Hematology, University Hospital of Salamanca, Paso de San Vicente 52 182, 37007 Salamanca, Spain
Curr Treat Options Oncol 4:247-58. 2003..However, in MM, several specific adjuvant therapies have also been introduced (eg, bisphosphonates and erythroid-stimulating factors), which have conferred a key role to supportive therapy in the general treatment of patients with MM... - In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myelomaEnrique M Ocio
Department of Hematology, University Hospital and Cancer Research Center, University of Salamanca P San Vicente, 58 182, 37007 Salamanca, Spain
Haematologica 95:794-803. 2010..We explored the antimyeloma activity of triple combinations of these well-established schemes with panobinostat, a novel deacetylase inhibitor with a multi-targeted profile... - The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patientsBruno Paiva
Hospital Universitario de Salamanca, Salamanca, Spain
Blood 114:4369-72. 2009..This trial was registered at www.clinicaltrials.gov as NCT00560053... - Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical valueMaria Belen Vidriales
Department of Hematology, University Hospital, Salamanca, Spain
Blood 101:4695-700. 2003.... - Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage responseEnrique Colado
Centro de Investigacion del Cancer, IBMCC CSIC Universidad de Salamanca, Salamanca, Spain
Haematologica 96:687-95. 2011..We investigated the antileukemic activity and mechanism of action of zalypsis, a novel alkaloid of marine origin... - New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findingsEnrique M Ocio
Servicio de Hematologia, Hospital Universitario de Salamanca, Salamanca, Spain
Lancet Oncol 9:1157-65. 2008..Unfortunately, the single-agent clinical activity of most of these new drugs has been limited; nevertheless, their effectiveness might be enhanced by their rational combination with each other or with conventional agents... - Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patientsMaria E Sarasquete
Servicio de Hematologia, Hospital Universitario, Centro de Investigación del Cáncer IBMCC USAL CSIC, Salamanca, Spain
Haematologica 96:468-71. 2011..02). By contrast, no differences in the expression of Drosha among these groups of patients were observed. Our data suggest that Dicer expression may play an important role in the progression and prognosis of monoclonal gammopathies... - Immunologic monitoring in adults with acute lymphoblastic leukemiaMaria Belen Vidriales
Hematology Department, University Hospital of Salamanca, Paseo de San Vicente 58 182, 37007 Salamanca, Spain
Curr Oncol Rep 5:413-8. 2003.... - Minimal residual disease monitoring by flow cytometryMaría B Vidriales
Department of Haematology, University Hospital, Paseo de San Vicente 58 182, 37007, Salamanca, Spain
Best Pract Res Clin Haematol 16:599-612. 2003..Current knowledge indicates that MRD studies using well-tested methodologies are clinically useful and should be incorporated into the clinical management of patients with acute leukaemia... - Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaksEnrique M Ocio
Centro de Investigacion del Cancer, Instituto de Biologia Molecular y Celular del Cancer Centro de Superior de Investigaciones Cientificas Universidad de Salamanca, Spain
Blood 113:3781-91. 2009..The potent in vitro and in vivo antimyeloma activity of Zalypsis uncovers the high sensitivity of tumor plasma cells to DSBs and strongly supports the use of this compound in MM patients... - Bone remodelation markers are useful in the management of monoclonal gammopathiesJose M Hernandez
Department of Hematology, Hospital General of Segovia, Spain
Hematol J 5:480-8. 2004..01). BRM and BFM, especially the ratios, are useful in the evaluation of bone lesions in patients with monoclonal gammopathies... - Limbus damage in ocular graft-versus-host diseaseRebeca Lorenzo Pérez
Servicio de Oftalmologia, Universidad de Salamanca, Salamanca, Spain
Biol Blood Marrow Transplant 17:270-3. 2011..Our results represent a major finding that allows us to define a model for evaluating new therapeutic strategies for treating ocular GVHD prior to their use in clinical setting... - Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myelomaBruno Paiva
Hospital Universitario de Salamanca, Salamanca, Spain
J Clin Oncol 29:1627-33. 2011..To investigate the impact of immunophenotypic response (IR) versus complete response (CR) and CR plus normal serum free light chain (sFLC) ratio (stringent CR) in elderly patients with multiple myeloma (MM) treated with novel agents... - The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotypeEnrique Colado
Department of Haematology, Hospital Universitario de Salamanca, Salamanca, Spain
Haematologica 93:57-66. 2008..We investigated the effects of bortezomib on the growth and survival of AML cells...